This activity is expired and is no longer available for CME credit.


RetinaCME® Presents Updates from Vancouver: Best of Ophthalmology Research - Transitioning Treatment in Diabetic Retinopathy

Author(s)/Faculty: Rishi P. Singh, MD; Arshad M. Khanani, MD, MA; Andrew A. Moshfeghi, MD, MBA
Release Date: 5/9/2019Expiration Date: 5/8/2020
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Diabetic retinopathy (DR) continues to be a leading cause of blindness worldwide. However, early diagnosis and prompt treatment with laser and/or intravitreal anti-vascular endothelial growth factor (VEGF) therapy has been shown to effectively prevent vision loss. Analysis of data from studies of diabetic macular edema have demonstrated that anti-VEGF therapies are effective in the treatment of DR as well. As data from clinical studies continue to develop for the utilization of anti-VEGF therapies in DR, it is imperative that these findings are incorporated into clinical practice for the optimization of outcomes in these patients. In this educational activity, recorded during an annual association meeting in Vancouver, British Columbia, experts in the field review new evidence regarding the treatment of proliferative and nonproliferative diabetic retinopathy as well as evaluate findings from emerging clinical trials pertaining to the optimization of management strategies for patients with DR.